

Seaside Therapeutics research sees possible autism treatment

Mass High Tech: The Journal of New England Technology

Seaside Therapeutics Inc. in Cambridge Wednesday published its latest research results for its disease-modifying drug candidate STX209 that shows promise as a treatment for fragile X syndrome and autism, the most prevalent form of intellectual disability.

Source URL (retrieved on 01/26/2015 - 4:15pm):

<http://www.mdtmag.com/news/2012/09/seaside-therapeutics-research-sees-possible-autism-treatment>